Reprogramming the heart is real but not yet a routine treatment. Two distinct strategies dominate: (1) direct cardiac reprogramming, converting scar-forming fibroblasts into new heart muscle inside the body with transcription factors (GATA4/MEF2C/TBX5), which works in mice and pigs but has never entered a human trial; and (2) cell transplantation of iPSC-derived cardiomyocytes, which has now reached humans and, in early 2026, achieved the world's first regulatory approval.
The single biggest 2026 milestone: On March 6, 2026, Japan's Ministry of Health, Labour and Welfare granted conditional and time-limited marketing approval to Cuorips Inc.'s allogeneic iPSC-derived cardiomyocyte sheet therapy ("ReHeart," development code IPSOC-1)—the world's first iPSC-cardiomyocyte therapy for heart failure—while Germany's NEJM BioVAT-HF engineered-heart-muscle trial and China's HEAL-CHF randomized trial reported the first controlled human efficacy and safety data.
Direct reprogramming lags cell therapy by roughly a decade. No direct-reprogramming approach is in humans; Tenaya Therapeutics' single-AAV reprogramming program (MYOCD+ASCL1+miR-133) remains preclinical (candidate-selection stage) after showing durable benefit in pig and rat infarct models. Key barriers remain low human reprogramming efficiency, safe delivery, arrhythmia risk, and immune response.
1. Direct cardiac reprogramming (fibroblast-to-cardiomyocyte, in vivo). The field began with Masaki Ieda and Deepak Srivastava's 2010 Cell paper showing that three transcription factors—Gata4, Mef2c, Tbx5 (GMT)—convert mouse fibroblasts into induced cardiomyocyte-like cells (iCMs), followed by the landmark 2012 Nature demonstration (Qian, Srivastava et al.) of in vivo reprogramming after coronary ligation. Adding Hand2 (GHMT) improved efficiency. In mice, in vivo reprogramming can approach 10–15% efficiency and reduces scar size while improving function, but the same factors are insufficient and far less efficient in human cells, which require larger, more complex cocktails. No human clinical trial of direct cardiac reprogramming has begun as of 2026.
2. iPSC-derived cardiomyocyte transplantation is now the clinical frontrunner. Multiple programs have reached patients: Japan's Cuorips/Osaka (Sawa) heart-muscle sheets, Heartseed/Novo Nordisk's HS-001 spheroids, China's HELP Therapeutics, and Germany's Repairon engineered heart muscle. In early 2026, Japan granted the world's first conditional/time-limited approval to an iPSC-cardiomyocyte product.
3. Other strategies remain preclinical or early. modRNA (transient mRNA) delivery of reprogramming factors, small-molecule cocktails, microRNA combinations (miR-1/133/208/499), exosome/extracellular-vesicle therapies, and AAV/Sendai-virus gene delivery are all under active investigation, mostly in animals.
4. Leading groups: Deepak Srivastava (Gladstone Institutes/UCSF; co-founder of Tenaya Therapeutics), Masaki Ieda (Keio/formerly University of Tsukuba), Li Qian (UNC), Wolfram-Hubertus Zimmermann (Göttingen/Repairon), Yoshiki Sawa (Osaka/Cuorips), and Keiichi Fukuda (Keio/Heartseed).
5. Clinical proximity: Cell transplantation is closest (first approval achieved). Direct reprogramming is roughly a decade behind, still preclinical.
6. 2024–2026 news: Cuorips approval (March 2026); BioVAT-HF NEJM publication (2026); HEAL-CHF Nature Medicine randomized trial (2026); Tenaya AHA 2025 pig reprogramming data; Ieda's 2024 AAV-targeting-fibroblast paper.
The adult human heart cannot meaningfully regenerate. After a myocardial infarction (MI), lost cardiomyocytes are replaced by fibroblasts that form a non-contractile scar. Because fibroblasts make up roughly half of all heart cells, they are an attractive in-situ reservoir: if they could be converted directly into working cardiomyocytes, the scar itself would become new muscle—no cell manufacturing or transplantation needed. The scale of unmet need is large: more than 64 million people worldwide live with heart failure, and patients with advanced disease face annual mortality rates approaching 50% despite optimal medical therapy (per the Artificial Organs review of BioVAT-HF).
The foundational discovery came from Masaki Ieda, then in Deepak Srivastava's lab, in a 2010 Cell paper: forced expression of Gata4, Mef2c, and Tbx5 (GMT) reprogrammed mouse cardiac fibroblasts into iCMs in vitro. In 2012, Qian, Srivastava and colleagues showed in Nature that delivering GMT directly into mouse hearts after coronary ligation reprogrammed resident fibroblasts into cardiomyocyte-like cells in vivo, reducing scar and improving function. pas Song and colleagues showed adding Hand2 (GHMT) boosted efficiency.
Efficiency improvements over 15 years have come from: additional transcription factors (Hand2, Myocd, Mesp1, Akt1, Sall4); microRNAs (miR-1, miR-133, miR-208, miR-499, "miR combo"); small molecules (TGF-β and Rho-kinase/WNT inhibitors, which raised efficiency up to ~60% in embryonic fibroblasts in one study; vitamin C; the "2C" cocktail of SB431542 and baricitinib); and better delivery vectors. A 2025 study (Honda, Ieda et al., Biochemical and Biophysical Research Communications) shortened and optimized the MEF2C and GATA4 coding sequences so the polycistronic cocktail fits within size-limited AAV vectors—an explicit step toward clinical translation.
The persistent problem is the human/mouse gap. GMT alone reprograms mouse cells but is inadequate for human fibroblasts, which need extra factors (e.g., adding ESRRG, MESP1, MYOCD, ZFPM2, or MGT plus miR-133) and still yield lower efficiency and more partially reprogrammed, immature cells. sciencedirect A 2026 Perturb-seq study identified calreticulin (Calr) as a top barrier to in vivo reprogramming, sciencedirect and a 2025 study implicated cellular senescence (via Rb1) as another—pointing to next-generation approaches that combine reprogramming factors with barrier-removal.
Human trial status: none. As of 2026 there is no registered human clinical trial of direct cardiac reprogramming. The most advanced translational effort is Tenaya Therapeutics (co-founded by Srivastava). Tenaya's approach, published in Circulation (online August 2023, DOI 10.1161/CIRCULATIONAHA.122.061542), packages a proprietary combination of three genes—an internally deleted myocardin (MyΔ3A), ASCL1, and miR-133—into a single novel engineered AAV that targets fibroblasts and de-targets existing cardiomyocytes (via miR-208 binding sites). In acute mouse and chronic rat MI models it produced significant, dose-dependent improvements in cardiac function sustained out to 29 weeks—the first such result in a chronic post-scar model. At the American Heart Association Scientific Sessions in November 2025, Tenaya (presenter Kathy Ivey, SVP Research) reported "significant and durable improvement of cardiac function in a pig model of ischemic heart failure" sec using this reprogramming cocktail delivered to the infarct border via a clinically relevant guided intramyocardial injection catheter. The program remains at the candidate-selection (preclinical) stage; Tenaya has not announced an IND or first-in-human timeline, and has not publicly disclosed the exact ejection-fraction improvement, dose levels, or durability timeframe from the pig study.
Masaki Ieda's group (now at Keio, previously Tsukuba) continues to lead the academic side, having pioneered non-integrating Sendai-virus delivery (2018), which generated ~100-fold more beating iCMs than retroviral GMT, and in September 2024 (Nakano, Sadahiro, Ieda et al., Stem Cell Reports) reported AAV vectors using a fibroblast-specific Postn promoter (AAV-DJ) that specifically targeted resident cardiac fibroblasts and improved function while reducing fibrosis. A December 2024 Circulation paper from the group extended cardiac reprogramming and Gata4 overexpression to heart failure with preserved ejection fraction (HFpEF).
Rather than reprogramming cells in place, this strategy manufactures cardiomyocytes from induced pluripotent stem cells (iPSCs) outside the body and transplants them. This field has decisively reached the clinic:
Cuorips / Osaka University (Yoshiki Sawa): iPSC-derived cardiomyocyte "patches" (sheets, ~4–5 cm, ~0.1 mm thick) applied to the heart surface; they work partly by paracrine cytokine release promoting angiogenesis rather than pure remuscularization. After testing in eight patients, Cuorips applied for approval in April 2025 and, per its March 6, 2026 press release, "Japan's Ministry of Health, Labour and Welfare (MHLW) has granted conditional and time-limited marketing approval for its allogeneic iPSC-derived cardiomyocyte sheet therapy (Development Code: IPSOC-1)"—the world's first such approval, for severe heart failure due to ischemic cardiomyopathy. Per Cuorips' TSE timely disclosure, "a post-marketing surveillance study targeting 75 cases will be conducted... aiming to commence sales in Japan around autumn 2026," with full approval requiring efficacy data gathered over seven years.
Heartseed / Novo Nordisk (Keiichi Fukuda): HS-001, allogeneic iPSC-derived purified ventricular cardiomyocyte spheroids injected intramyocardially. The Phase 1/2 LAPiS study (NCT04945018, 10 patients, two dose cohorts of 50M and 150M cells) completed enrollment in early 2025; 52-week topline results were presented at ESC Congress 2026. A new endocardial-delivery (catheter) trial, EMERALD (NCT07347197), began in 2026, with the first patient dosed at Shinshu University.
HELP Therapeutics (China): HiCM-188 intramyocardial injection; a pivotal randomized trial (REVIVE-HEART, NCT07496372) is recruiting with a start date of April 2026. The HEAL-CHF randomized trial (20 patients, published in Nature Medicine 2026) tested allogeneic iPSC-cardiomyocytes plus CABG versus CABG alone.
Repairon / University Medical Center Göttingen (Wolfram-Hubertus Zimmermann): Engineered heart muscle (EHM) "biologic ventricular assist tissue" (BioVAT) allografts—iPSC-derived cardiomyocytes plus stromal cells in collagen—implanted nejm epicardially. The Phase 1/2 BioVAT-HF trial (NCT04396899) published interim results in the New England Journal of Medicine in 2026, preceded by a 2024/2025 Nature primate study.
Key clinical signals and cautions: The HEAL-CHF randomized trial (Zhang, Menasché, Fan et al., Nature Medicine 2026, DOI s41591-026-04605-1; n=20, 18 male/2 female, LVEF ≤45%) found no significant between-group differences in ejection fraction, ventricular volumes, scar size, NYHA class, or quality-of-life scores at 12 months, though some secondary measures (exercise capacity, myocardial perfusion, regional wall function) showed signals. On its primary safety endpoint, "neither sustained ventricular tachycardia nor tumorigenicity was observed in either patient group." However, all 10 cell-treated patients developed accelerated idioventricular rhythm (typically days 5–7 post-transplant), nature and two developed clinically significant ventricular tachycardia (>140 bpm, peaking weeks 2–3).
The BioVAT-HF interim analysis (Zimmermann et al., N Engl J Med 2026;394(20):1991-2001) reported, among 16 patients at the 20-unit maximal safe dose (12 completing 3-month follow-up): "the least-squares mean increase in the target-wall thickness was 4.5 mm (90% CI, 3.7 to 5.4; P<0.001), the increase in the left ventricular ejection fraction was 3.9 percentage points (90% CI, 0.9 to 6.8; P=0.04), and the increase in the KCCQ-OSS was 6.7 points." Safety was mixed: "All 20 patients experienced at least one adverse event, and three deaths occurred, none attributed to BioVAT"; ventricular tachycardia occurred in 3 patients, and—importantly—one explanted heart (from a patient who went on to transplant) confirmed genuine human cardiac remuscularization by the graft. This transient arrhythmia pattern—related to immature/automaticity-prone graft cells—recurs across primate and human studies and is the central safety issue for transplantation approaches. Japan's two 2026 iPSC approvals (Cuorips for heart, and Sumitomo's for Parkinson's) also generated scientific debate over whether small Phase 1/2 studies suffice for approval.
modRNA (modified mRNA): Building on COVID-vaccine technology, modRNA delivers reprogramming or pro-regenerative factors transiently, avoiding permanent genomic integration—an attractive safety feature. Kaur et al. (2021) injected a cocktail of seven modRNAs to induce reprogramming; much modRNA work now targets cardiomyocyte proliferation (VEGFA, Lin28a, CCND2, Pkm2) rather than fibroblast conversion. Still preclinical.
Small-molecule / chemical reprogramming: Fully chemical cocktails (e.g., Cao et al.'s nine small molecules for human fibroblasts) can generate iCMs without genetic vectors, an appealing route for avoiding gene-therapy risks, but efficiency and reproducibility remain limiting.
Exosomes / extracellular vesicles (EVs): Mesenchymal-stem-cell- and cardiosphere-derived EVs reduce fibrosis, promote angiogenesis, and improve function in rodent and porcine MI models, largely via paracrine/anti-inflammatory effects rather than remuscularization. Reviews note no dedicated clinical trials of exosomes specifically for MI are yet underway, and long-term safety data are limited.
Gene therapy (AAV, Sendai virus): AAV is the clinically dominant vector; the challenge for reprogramming is targeting fibroblasts (not cardiomyocytes) and fitting multi-gene cocktails into AAV's limited cargo. Progress includes Ieda's Postn-promoter AAV-DJ (2024), AAV1 fibroblast tropism, Tenaya's engineered capsid, and CRISPR-activation approaches (2026 proof-of-concept). Notably, Tenaya's separate AAV gene-replacement therapies (TN-201 for MYBPC3 hypertrophic cardiomyopathy, TN-401 for PKP2 ARVC) are already in Phase 1b/2a trials, demonstrating that cardiac AAV gene therapy is clinically feasible—though those are gene replacement, not reprogramming.
Human reprogramming efficiency is far lower than in mice and yields immature, heterogeneous iCMs.
Delivery and fibroblast targeting—getting factors specifically into scar fibroblasts without transducing other cells, using clinically safe (non-integrating or well-controlled) vectors.
Arrhythmia risk—both immature transplanted cardiomyocytes and newly reprogrammed iCMs can create electrical instability; transient ventricular arrhythmias are consistently observed.
Immune response—allogeneic iPSC products require immunosuppression; direct reprogramming largely sidesteps this by using the patient's own cells in place.
Scale and manufacturing (for transplantation) and scar-tissue targeting (for reprogramming).
For a general reader or non-specialist stakeholder tracking this field:
Treat "reprogramming the heart" as two separate timelines. iPSC-cardiomyocyte transplantation is now a real (if conditionally approved, limited) therapy in Japan; direct in-situ reprogramming is still preclinical and years from patients. Do not conflate the two when reading headlines.
Watch these near-term readouts as milestones: (a) Cuorips ReHeart post-marketing 75-case surveillance data (from ~autumn 2026) for real-world efficacy/safety; (b) Heartseed HS-001 full LAPiS/EMERALD results; (c) BioVAT-HF longer-term (beyond 3-month) follow-up; (d) any Tenaya IND filing for its reprogramming program.
Use arrhythmia and durable ejection-fraction gain as the decision thresholds. The benchmark that would move transplantation from "promising" to "practice-changing" is a randomized trial showing a clinically meaningful, sustained ejection-fraction or outcome improvement without graft-related sustained ventricular arrhythmia. HEAL-CHF's neutral primary efficacy endpoint shows this bar has not yet been cleared; BioVAT-HF's modest but statistically significant 3.9-point EF gain is an encouraging early signal that needs replication.
For direct reprogramming, the threshold to watch is the first-in-human IND. A large-animal (pig) efficacy result delivered by catheter (as Tenaya reported in 2025) is the last major preclinical gate; an IND filing would be the signal that human testing is imminent.
Temper expectations on exosomes and small molecules—these are earlier still and, for exosomes, may act more as anti-fibrotic/pro-angiogenic adjuncts than true muscle-regenerators.
Company and trial-derived claims (Tenaya, Heartseed, Cuorips) come substantially from press releases and investor materials, which emphasize positive framing; several key efficacy figures (e.g., Tenaya's pig-study ejection-fraction numbers) have not been disclosed in peer-reviewed form.
Japan's conditional approvals are explicitly time-limited and based on small (single-digit to low-double-digit patient) studies; efficacy is provisional pending post-marketing data collected over seven years, and the approval standard has been publicly questioned by scientists.
Mouse-to-human extrapolation is unreliable in this field: efficiencies, factor requirements, and heart physiology (beating rate, electrical coupling) differ substantially, and many in vivo "reprogramming" benefits in animals may partly reflect angiogenesis or anti-fibrotic effects rather than bona fide new muscle.
Efficiency percentages vary widely by cell type (embryonic vs. adult, mouse vs. human), vector, and assay, so headline numbers (e.g., "~60%") are not directly comparable across studies.
Several 2026-dated sources are recent journal articles and reputable news outlets; a few supporting details come from secondary aggregators and should be considered corroborated-but-secondary.